Details

Autor(en) / Beteiligte

• Winklmeier, Stephan
• Schlüter, Miriam
• Spadaro, Melania
• Thaler, Franziska S
• Vural, Atay
• Gerhards, Ramona
• Macrini, Caterina
• Mader, Simone
• Kurne, Aslı
• Inan, Berin
• Karabudak, Rana
• Özbay, Feyza Gül
• Esendagli, Gunes
• Hohlfeld, Reinhard
• Kümpfel, Tania
• Meinl, Edgar

Titel

Identification of circulating MOG-specific B cells in patients with MOG antibodies

Ist Teil von

• Neurology : neuroimmunology & neuroinflammation, 2019-11, Vol.6 (6), p.625-625

Ort / Verlag

United States: American Academy of Neurology

Erscheinungsjahr

2019

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• OBJECTIVETo identify circulating myelin oligodendrocyte glycoprotein (MOG)-specific B cells in the blood of patients with MOG antibodies (Abs) and to determine whether circulating MOG-specific B cells are linked to levels and epitope specificity of serum anti-MOG-Abs. METHODSWe compared peripheral blood from 21 patients with MOG-Abs and 26 controls for the presence of MOG-specific B cells. We differentiated blood-derived B cells in vitro in separate culture wells to Ab-producing cells via engagement of Toll-like receptors 7 and 8. We quantified the anti-MOG reactivity with a live cell–based assay by flow cytometry. We determined the recognition of MOG epitopes with a panel of mutated variants of MOG. RESULTSMOG-Ab–positive patients had a higher frequency of MOG-specific B cells in blood than controls, but MOG-specific B cells were only detected in about 60% of these patients. MOG-specific B cells in blood showed no correlation with anti-MOG Ab levels in serum, neither in the whole group nor in the untreated patients. Epitope analysis of MOG-Abs secreted from MOG-specific B cells cultured in different wells revealed an intraindividual heterogeneity of the anti-MOG autoimmunity. CONCLUSIONSThis study shows that patients with MOG-Abs greatly differ in the abundance of circulating MOG-specific B cells, which are not linked to levels of MOG-Abs in serum suggesting different sources of MOG-Abs. Identification of MOG-specific B cells in blood could be of future relevance for selecting patients with MOG-Abs for B cell–directed therapy.